Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. "We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. The company will need to test their drug candidate in clinical trials – Yourway is the market leader that can help assure even the most sensitive products are safely transported on the trial journey.